BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1848996)

  • 21. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
    Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
    J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
    Messeih AA; Schweitzer JM; Lipton A; Harvey HA; Simmonds MA; Stryker JA; Ricci JA; Hoffman SL; Gottleib RJ; Dixon RH
    Cancer Treat Rep; 1987 Jan; 71(1):61-6. PubMed ID: 3024828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1150-6. PubMed ID: 8260367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group.
    Urban T; Baleyte T; Chastang CL; Jeannin L; Delaval P; Zaegel M; Mornet M; Coetmeur D; Lebeau B
    Lung Cancer; 1999 Aug; 25(2):105-13. PubMed ID: 10470844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
    Murray N; Shah A; Osoba D; Page R; Karsai H; Grafton C; Goddard K; Fairey R; Voss N
    J Clin Oncol; 1991 Sep; 9(9):1632-8. PubMed ID: 1651995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
    Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
    Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
    J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
    Gridelli C; Contegiacomo A; Lauria R; Gentile M; Airoma G; De Placido S; Perrone F; Ferrante G; Bianco AR
    Tumori; 1991 Dec; 77(6):506-10. PubMed ID: 1666468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Alberto P; Bleher EA; Ludwig C; Siegenthaler P; Martinelli G; Sauter C; Schatzmann E; Senn HJ
    Ann Oncol; 1994 Dec; 5(10):921-8. PubMed ID: 7696164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR; Fuks JZ; Ettinger DS; Chang AY; Ruckdeschel JC; Phan SC; Blum RH
    Cancer J Sci Am; 2000; 6(1):34-9. PubMed ID: 10696737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
    Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
    J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
    Jett JR; Everson L; Therneau TM; Krook JE; Dalton RJ; Marschke RF; Veeder MH; Brunk SF; Mailliard JA; Twito DI
    J Clin Oncol; 1990 Jan; 8(1):33-8. PubMed ID: 2153193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
    Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
    Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclic alternating combination chemotherapy for small cell lung cancer.
    Reddy SK; Takita H; Lane WW; Vincent RG; Chen TY; Caracandas JE; Regal AM
    Cancer Chemother Pharmacol; 1984; 12(3):190-3. PubMed ID: 6323044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgery for cure of small cell bronchial carcinoma (SCLC) at early stages and postoperative combined modality treatment.
    Karrer K; Denck H; Karnicka-Mlodkowska H; Drings P; Erzen J; Salzer GM;
    J Chemother; 1989 Jul; 1(4 Suppl):1207-8. PubMed ID: 16312836
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer.
    Erkişi M; Unsal M; Tunali C; Burgut R; Doran F
    J Chemother; 1993 Feb; 5(1):56-9. PubMed ID: 8384659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1157-66. PubMed ID: 7505104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.